JOURNAL SCANS: RESEARCH

Page 1 of 301

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Three Studies Published in New England Journal of Medicine Aimed to Clarify the Efficacy and Safety of Lenalidomide Maintenance Therapy in Multiple Myeloma, in Both Post-Transplant and Non-Transplant Settings

2012 May 10, N Engl J Med

Three randomized placebo-controlled trials examining the role of lenalidomide maintenance in multiple myeloma demonstrated significant benefits in progression-free survival, but only one trial demonstrated...

Adjuvant Radiotherapy Versus Observation Alone for Patients at Risk of Lymph-Node Field Relapse After Therapeutic Lymphadenectomy for Melanoma: A Randomised Trial

BH Burmeister, MA Henderson, J Ainslie, JF Thompson, et al, 2012 May 9, Lancet Oncol

Results of this randomized trial confirmed that the risk of lymph–node field relapse following complete surgical resection is reduced through adjuvant radiation in patients with metastatic melanoma. Overall...

Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis

C de Martel, J Ferlay, S Franceschi, J Vignat, F Bray, D Forman, M Plummer, 2012 May 9, Lancet Oncol

Authors of this report estimate that approximately 1 in 5 deaths due to cancer worldwide could be attributed to infectious agents. Infections by HPV, H. pylori, HBV, and HCV, cited in particular, are preventable. Abstract Background:...

Bevacizumab in Combination With Chemotherapy as First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

E Van Cutsem, S de Haas, Y-K Kang, A Ohtsu, NC Tebbutt, JM Xu, WP Yong, B Langer, P Delmar, SJ Scherer, MA Shah, 2012 May 7, J Clin Oncol

Results of this pre-planned analysis of biomarkers collected to determine survival outcome of patients with gastric cancer treated with bevacizumab indicated that plasma VEGF-A and tumor neuropilin-1 levels...

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

T Bachelot, C Bourgier, C Cropet, E Pujade-Lauraine, et al, 2012 May 7, J Clin Oncol

EXPERT COMMENTARY

Tamoxifen and everolimus combination therapy was associated with clinical benefit and overall survival compared with tamoxifen monotherapy in women with metastatic breast cancer progressing on aromatase...

Improved Survival in MDS Patients Receiving Iron Chelation Therapy – A Matched Pair Analysis of 188 Patients From the Düsseldorf MDS Registry

J Neukirchen, F Fox, A Kundgen, K Nachtkamp, C Strupp, R Haas, U Germing, N Gattermann, 2012 May 5, Leuk Res

Results of this retrospective analysis of patients with myelodysplastic syndrome receiving chronic transfusion with iron chelation compared with matched patients without iron chelation confirmed that median...

Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer

M Schlumberger, B Catargi, I Borget, E Benhamou, et al, 2012 May 3, N Engl J Med

Two major contemporaneous studies with 2×2 factorial randomization between low- and high-dose radioiodine, and between recombinant thyrotropin and thyroid hormone withdrawal, found noninferiority in the...

Risk Categories and Refractory CLL in the Era of Chemoimmunotherapy

T Zenz, JG Gribben, M Hallek, H Dohner, MJ Keating, S Stilgenbauer, 2012 May 3, Blood

The authors of this paper make a plea for rethinking the current definition of refractory CLL and for refining risk models in order to standardize diagnostic criteria and the assessment of treatment response. Abstract Standardized...

Efficacy of Docetaxel-Based Chemotherapy Following Ketoconazole in Metastatic Castration-Resistant Prostate Cancer: Implications for Prior Therapy in Clinical Trials

GR Pond, AJ Armstrong, MD Galsky, BA Wood, L Leopold, G Sonpavde, 2012 May 3, Urol Oncol

Results of this retrospective analysis of a phase II trial of men who received first-line docetaxel for metastatic castration-resistant prostate cancer showed worse outcomes for those with prior ketoconazole...

An Open-Label, Single-Arm, Phase 2 (PX-171-004) Study of Single-Agent Carfilzomib in Bortezomib-Naive Patients With Relapsed and/or Refractory Multiple Myeloma

R Vij, M Wang, JL Kaufman, S Lonial, AJ Jakubowiak, AK Stewart, V Kukreti, S Jagannath, KT McDonagh, M Alsina, NJ Bahlis, FJ Reu, NY Gabrail, A Belch, JV Matous, P Lee, P Rosen, M Sebag, DH Vesole, LA Kunkel, SM Wear, AF Wong, RZ Orlowski, DS Siegel, 2012 May 3, Blood

Results of this small phase II trial of bortezomib-naive patients with relapsed/refractory myeloma treated with single-agent carfilzomib are encouraging, particularly potential long-term use without significant...

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Page 1 of 301

Comment Print page RSS feeds

About Our Journal Scans

View a list of journals that the OncologySTAT editorial team scans every week in order to bring you the most practice-relevant original research and review articles.

View list ›

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Sign-up now ›